ST Germain D J Co. Inc. Purchases 20,410 Shares of Becton, Dickinson and Company (NYSE:BDX)

Share on StockTwits

ST Germain D J Co. Inc. boosted its position in Becton, Dickinson and Company (NYSE:BDX) by 56.8% during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 56,352 shares of the medical instruments supplier’s stock after purchasing an additional 20,410 shares during the period. ST Germain D J Co. Inc.’s holdings in Becton, Dickinson and were worth $13,112,000 as of its most recent SEC filing.

Several other institutional investors have also recently added to or reduced their stakes in the business. Balentine LLC boosted its holdings in shares of Becton, Dickinson and by 45.3% in the second quarter. Balentine LLC now owns 138 shares of the medical instruments supplier’s stock worth $33,000 after buying an additional 43 shares during the last quarter. Douglas Lane & Associates LLC grew its position in shares of Becton, Dickinson and by 2.0% during the 2nd quarter. Douglas Lane & Associates LLC now owns 2,443 shares of the medical instruments supplier’s stock valued at $585,000 after acquiring an additional 47 shares during the period. Mcrae Capital Management Inc. increased its stake in shares of Becton, Dickinson and by 0.4% in the 2nd quarter. Mcrae Capital Management Inc. now owns 11,647 shares of the medical instruments supplier’s stock worth $2,787,000 after purchasing an additional 50 shares in the last quarter. Naples Global Advisors LLC increased its stake in shares of Becton, Dickinson and by 2.6% in the 2nd quarter. Naples Global Advisors LLC now owns 1,985 shares of the medical instruments supplier’s stock worth $475,000 after purchasing an additional 50 shares in the last quarter. Finally, Long Road Investment Counsel LLC raised its holdings in Becton, Dickinson and by 0.3% in the 2nd quarter. Long Road Investment Counsel LLC now owns 16,858 shares of the medical instruments supplier’s stock worth $4,034,000 after purchasing an additional 50 shares during the period. Institutional investors and hedge funds own 74.40% of the company’s stock.

BDX traded down $1.03 during trading hours on Friday, reaching $231.87. The company’s stock had a trading volume of 1,255,875 shares, compared to its average volume of 1,868,489. The business’s 50-day moving average is $237.17 and its 200-day moving average is $245.57. The company has a debt-to-equity ratio of 0.72, a current ratio of 1.54 and a quick ratio of 1.07. The stock has a market cap of $67.21 billion, a PE ratio of 84.93, a P/E/G ratio of 2.16 and a beta of 0.83. Becton, Dickinson and Company has a fifty-two week low of $197.75 and a fifty-two week high of $286.72.

Becton, Dickinson and (NYSE:BDX) last issued its quarterly earnings results on Tuesday, November 10th. The medical instruments supplier reported $2.79 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $2.52 by $0.27. The company had revenue of $4.78 billion for the quarter, compared to the consensus estimate of $4.48 billion. Becton, Dickinson and had a return on equity of 13.30% and a net margin of 5.11%. Becton, Dickinson and’s revenue was up 4.4% on a year-over-year basis. During the same quarter in the prior year, the business earned $3.31 EPS. Analysts expect that Becton, Dickinson and Company will post 12.5 EPS for the current year.

A number of analysts have commented on the company. Raymond James reduced their price target on Becton, Dickinson and from $285.00 to $270.00 and set an “outperform” rating for the company in a research report on Monday, October 12th. The Goldman Sachs Group upgraded shares of Becton, Dickinson and from a “buy” rating to a “conviction-buy” rating in a research report on Friday, October 2nd. UBS Group upped their price target on shares of Becton, Dickinson and from $265.00 to $280.00 and gave the company a “neutral” rating in a research note on Monday, August 10th. Morgan Stanley reduced their target price on Becton, Dickinson and from $270.00 to $262.00 and set an “equal weight” rating on the stock in a research report on Friday, November 6th. Finally, TheStreet cut shares of Becton, Dickinson and from a “b” rating to a “c+” rating in a report on Monday, September 21st. One equities research analyst has rated the stock with a sell rating, seven have assigned a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company. Becton, Dickinson and presently has a consensus rating of “Buy” and an average target price of $277.93.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral IV and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, IV fluids, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps and dedicated disposables, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems.

Read More: How is net asset value different from market price?

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE:BDX).

Institutional Ownership by Quarter for Becton, Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.